Quick Facts

• May be administered for the treatment of infantile spasms in infants under two years of age.
• Used for managing acute exacerbations of multiple sclerosis in adults.
• May serve as an adjunctive treatment for certain rheumatic, collagen, and dermatologic disorders, often for short-term use during an acute episode.

ACTH (Adrenocorticotropic Hormone, also known as repository corticotropin injection) is approved for a variety of conditions, often when other typical treatments have not been sufficiently effective. It is used in the management of infantile spasms in young children. In adults, it is also indicated for the treatment of acute exacerbations of multiple sclerosis.

Furthermore, ACTH may be employed as a temporary, additional therapy to help address severe acute and chronic allergic and inflammatory processes involving the eye, such as iritis and optic neuritis. It may be considered for symptomatic sarcoidosis, certain rheumatic disorders (like psoriatic arthritis), and specific collagen diseases (including systemic lupus erythematosus), typically to help the patient manage an acute flare. ACTH is also used to help induce a remission of proteinuria in certain forms of nephrotic syndrome.

Eligibility Map: Who Can and Cannot Use ACTH (Corticotropin)

The population eligibility for Corticotropin is defined by official regulatory documentation, outlining specific contraindications, age limitations, and conditions requiring restricted use.

Contraindicated Populations (Must Not Use)

ACTH is strictly contraindicated in patients with specific infectious, autoimmune, and cardiovascular conditions, including Systemic Fungal Infections, Ocular Herpes Simplex, Scleroderma, Osteoporosis, and a history of Peptic Ulcer [Source 1.2]. Use is also prohibited in patients with Congestive Heart Failure, Uncontrolled Hypertension, or those with pre-existing Primary Adrenocortical Insufficiency [Source 1.2].

Age- and Condition-Based Restrictions

Population Group	Eligibility Status
Infants/Children	Use is permitted for specific conditions (e.g., Infantile Spasms) but requires careful monitoring of growth and development during prolonged therapy [Source 1.4]. Children under two are contraindicated if suspected congenital infections are present [Source 1.2].
Pregnancy	Use is limited; it is permitted only if the potential benefit outweighs the potential risk of fetal harm, as stated in official labeling [Source 1.7].
Conditional Use	Use requires caution in patients with Renal Insufficiency, Cirrhosis of the Liver, Hypothyroidism, or Diabetes, as an enhanced drug effect or disease aggravation may occur [Source 1.5, 1.4].

Interactions with other medicines and products

The official regulatory profile for Corticotropin establishes specific restrictions and cautions concerning co-administration with other substances and medical procedures. These statements define mandatory constraints for use.

---

Contraindications and Procedural Cautions

Co-administration of Live or Live-Attenuated Vaccines is formally contraindicated when Corticotropin is administered at an immunosuppressive dosage. This prohibition is due to the potential for severe adverse reactions and a reduced vaccine efficacy. Separately, other immunization procedures must be approached with caution due to the potential for neurological complications and a resulting lack of antibody response. Furthermore, Aspirin requires caution when co-administered in patients with concurrent hypoprothrombinemia.

Pharmacodynamic and Exposure Interactions

The use of Corticotropin with Loop and Thiazide Diuretics or Amphotericin B carries an additive risk of hypokalemia (low serum potassium). Estrogen-Containing Drugs may enhance the systemic effects of the stimulated corticosteroids. This occurs due to a documented reduction in metabolic clearance resulting from estrogen-induced increases in Cortisol-Binding Globulin.

Substance and Timing Restrictions

Timing constraints require that other drugs be administered when an immediate therapeutic effect is desired, as maximal Corticotropin stimulation may be limited during the initial days of treatment. Dietary restrictions mandate the limitation of alcohol intake and the avoidance of excessive grapefruit juice consumption.

Targeted Adrenal Receptor Activation

The mechanism of Corticotropin begins with its action as a full agonist at the Melanocortin 2 Receptor ( MC2 R), located almost exclusively on the adrenal gland. This primary interaction triggers an intracellular signaling sequence, activating the cAMP pathway that is integral to initiating the cellular signaling required for steroidogenesis.

---

️ Potentiation of Endogenous Steroid Synthesis

The activated MC2 R signal rapidly accelerates the entire steroidogenesis cascade. Key proteins, such as the rate-limiting Steroidogenic Acute Regulatory Protein (StAR), are stimulated, significantly increasing the synthesis and secretion of Cortisol and adrenal androgens. This results in an increase of the body's own immunomodulatory hormones.

---

Systemic Anti-Inflammatory Modulation

The resulting high circulating levels of Cortisol mediate systemic effects by binding to intracellular Glucocorticoid Receptors ( GR) in immune and inflammatory cells throughout the body. This genomic action profoundly suppresses the expression of genes for pro-inflammatory mediators while enhancing the synthesis of anti-inflammatory proteins, leading to sustained physiological adjustments in the immune system.

Administration Methods

Adrenocorticotropic hormone (ACTH) is typically administered through injection. The specific method of delivery—whether subcutaneous or intramuscular—depends on the formulation of the medication and the underlying condition being addressed.

Preparation for Use

Before administration, the medication is usually brought to room temperature. This may involve holding the vial in the hands for several minutes. If the medication is a gel formulation, it may require gentle warming to ensure it reaches a consistency suitable for injection.

Injection Sites

Common sites for injection include the following areas, provided there is sufficient muscle or subcutaneous tissue:

• Thighs: The front or outer portion of the upper leg.
• Upper Arm: The deltoid area, used primarily for certain types of injections.
• Buttocks: Often utilized for intramuscular injections.

It is common practice to rotate the injection sites. This involves choosing a different location for each subsequent dose to minimize the risk of skin irritation or tissue changes at the site of injection.

Monitoring Response

Healthcare providers monitor the individual's response to the medication through various means. This often includes regular blood pressure checks and periodic laboratory tests to evaluate electrolyte levels and hormone production. These observations help determine how the body is responding to the treatment over time.

Research Evidence / Overview of studies for ACTH

Evidence for use in Infantile Spasms (West Syndrome)

Research into infantile spasms includes Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies focused on infants and young children, monitoring the frequency of spasms and measurements related to the characteristic brain activity patterns (hypsarrhythmia) by EEG. Short-term trials reported patterns of change in spasm frequency and EEG measurements in the observed populations. Comparative findings with other treatments were mixed. Research has not established the optimal dosage or duration, and limited information is available to fully establish long-term neurological health outcomes.

---

Evidence for use in Acute Exacerbations of Multiple Sclerosis

Research on ACTH for acute exacerbations of multiple sclerosis (MS) includes early placebo-controlled RCTs and studies comparing its use with standard high-dose corticosteroids. These studies focused on adults and monitored short-term neurological changes. Studies reported differences in measured outcomes between treated groups and placebo groups. Comparative evidence with high-dose corticosteroids described measured short-term outcomes that showed patterns similar to those observed with corticosteroids. Many foundational RCTs are older, and the findings apply only to the populations studied.

---

What is Still Uncertain About the ACTH Research Base

Several key gaps remain in the research landscape. For many indications, the optimal dosage and duration of ACTH treatment have not been established by existing studies. The evidence quality varies across studies, particularly for indications relying heavily on observational data, such as nephrotic syndrome. Long-term effects are not fully established, as follow-up durations were limited in many of the core studies. Furthermore, comparative evidence against newer standard-of-care treatments is lacking in some areas, meaning data are still emerging and certainty remains low in certain clinical scenarios.

Key Studies & References

1. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS
2. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel

Common questions about ACTH (FAQ)

Q: How quickly does ACTH start to work after the first dose?

ACTH is often supplied in a repository (gel) formulation designed for a sustained effect. According to official product information, the active ingredient is slowly absorbed over approximately 8 to 16 hours. When used in diagnostic tests, the effect on the adrenal gland can be observed much sooner, typically within an hour.

Q: Is ACTH considered a steroid medication?

No, ACTH is not itself a steroid. It is officially classified as a Pituitary Hormone and a Corticosteroid Secretagogue, which means it instructs the adrenal glands to increase the production and release of the body’s own natural steroids, such as cortisol. This difference in action is central to how the medicine works.

Q: What conditions is ACTH officially approved to treat?

Official drug labeling lists several conditions across different body systems where ACTH is indicated. These uses include infantile spasms and acute exacerbations of multiple sclerosis, as well as certain specified rheumatic, allergic, eye, skin, and fluid retention (edematous) states.

Q: Why does the information say ACTH should not be used by people with certain infections?

Official warnings from regulatory documents state that ACTH may increase the risks associated with infection. This is because the medicine can increase the risk of a new infection developing, or it may worsen an existing latent (hidden) infection. Furthermore, it may mask the usual signs, making it harder to recognize an infection.

Q: How long does the effect of one dose of ACTH usually last?

ACTH repository injection is designed for a sustained release of the active ingredient. According to product information, this sustained effect is achieved through slow absorption that typically takes 8 to 16 hours.

Q: What does it mean if I have a contraindication to ACTH?

A contraindication is a specific medical situation where using a medicine is not recommended because it may be harmful. Official guidelines list several conditions, such as systemic fungal infections or uncontrolled hypertension, for which the use of ACTH is strictly prohibited in regulatory documents due to the potential for serious complications.

Q: Does ACTH affect sleep patterns?

Official safety information states that insomnia (difficulty falling asleep or staying asleep) is listed as a possible adverse reaction. This effect is included in the category of behavioral and mood disturbances documented in the drug's regulatory profile.

Q: Is it normal to feel tired or weak when starting ACTH?

Official labeling lists muscle weakness and loss of muscle mass as potential musculoskeletal side effects. These documented effects are related to the medicine’s action on the musculoskeletal system.

Q: What are the official sources for learning about ACTH?

To find factual, regulatory information about ACTH, you can refer to official government-run sources. These include the labeling published by national regulatory agencies like the U.S. FDA (DailyMed) and public health bodies like the NIH (MedlinePlus).

Q: How long does ACTH stay in your system after stopping treatment?

The repository formulation is absorbed over several hours, typically 8 to 16 hours. However, the medicine's biological effect on the adrenal glands is longer-lasting. Because of this prolonged effect, a gradual reduction in dose (tapering) is required when ceasing treatment to prevent complications related to sudden discontinuation.

Q: Are there restrictions on driving or operating machinery while on ACTH?

While a specific, explicit restriction on driving or operating machinery is not provided in the regulatory labeling, official documents list potential neurological side effects. These include vertigo (dizziness) and changes in mood or behavior, such as euphoria or psychosis.

Q: How do official sources describe the side effect known as Cushingoid appearance?

The Cushingoid state is a risk noted for prolonged use of ACTH. Official sources describe this as a collection of physical changes, which can include weight gain primarily located in the trunk and face (facial puffiness), and the development of thin, fragile skin.

Q: What does the latest research say about ACTH safety?

Studies and official information indicate the need for careful monitoring during prolonged use. Key concerns are related to the effects of long-term steroid stimulation, which can include risks like bone density changes (osteoporosis), eye conditions (cataracts or glaucoma), and an increased susceptibility to infection.

Storage and Disposal of ACTH (Repository Corticotropin Injection)

The official instructions for storing ACTH (repository corticotropin injection) must be strictly followed to maintain product integrity.

---

Storage Requirements

ACTH must be stored in a refrigerator at temperatures between 36 F and 46 F (2 C and 8 C). The product must not be frozen and should be kept in its original carton for protection from light. Before use, the cold product must be allowed to warm to room temperature for at least 45 minutes; however, it should not be stored unrefrigerated for more than 24 hours. Once a multi-dose vial is first punctured, its in-use stability period is limited, and it must be discarded after 28 days or by the printed expiration date, whichever occurs first.

---

Disposal and Safety

All used needles, syringes, and injectors (sharps) must be placed immediately into an FDA-cleared sharps disposal container. Sharps and containers should never be thrown into household trash or standard recycling bins. The full sharps container must be disposed of according to local community guidelines for medical waste. The medication and the sharps container must always be kept out of the sight and reach of children.